The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to
                Evaluate the Potential of Ivermectin to Reduce COVID-19
                Transmission in low risk, non-severe COVID-19 patients in the
                first 48 hours after symptoms onset: A structured summary of a
                study protocol for a randomized control pilot trial

Chaccour, Carlos; Ruiz Castillo, Paula; Richardson, Mary-Ann; Moncunill Piñas, Gemma; Casellas, Aina; Carmona Torre, Francisco; Giráldez, Miriam; Schwartz Mota, Juana; Yuste, José R.; Azanza, José Ramón; Fernández, Miriam; Reina, Gabriel; Dobaño, Carlota, 1969-; Brew, Joe; Sadaba, Belen; Hammann, Felix; Rabinovich, Regina

The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

dc.contributor.author	Chaccour, Carlos
dc.contributor.author	Ruiz Castillo, Paula
dc.contributor.author	Richardson, Mary-Ann
dc.contributor.author	Moncunill Piñas, Gemma
dc.contributor.author	Casellas, Aina
dc.contributor.author	Carmona Torre, Francisco
dc.contributor.author	Giráldez, Miriam
dc.contributor.author	Schwartz Mota, Juana
dc.contributor.author	Yuste, José R.
dc.contributor.author	Azanza, José Ramón
dc.contributor.author	Fernández, Miriam
dc.contributor.author	Reina, Gabriel
dc.contributor.author	Dobaño, Carlota, 1969-
dc.contributor.author	Brew, Joe
dc.contributor.author	Sadaba, Belen
dc.contributor.author	Hammann, Felix
dc.contributor.author	Rabinovich, Regina
dc.date.accessioned	2021-03-01T07:28:48Z
dc.date.available	2021-03-01T07:28:48Z
dc.date.issued	2020-06-08
dc.date.updated	2021-02-26T19:00:57Z
dc.description.abstract	Objectives: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7 post-treatment.
dc.format.extent	4 p.
dc.format.mimetype	application/pdf
dc.identifier.issn	1745-6215
dc.identifier.pmid	32513289
dc.identifier.uri	https://hdl.handle.net/2445/174448
dc.language.iso	eng
dc.publisher	BioMed Central
dc.relation.isformatof	Reproducció del document publicat a: http://dx.doi.org/10.1186/s13063-020-04421-z
dc.relation.ispartof	Trials, 2020, vol. 21
dc.relation.uri	http://dx.doi.org/10.1186/s13063-020-04421-z
dc.rights	cc by (c) Chaccour et al., 2020
dc.rights.accessRights	info:eu-repo/semantics/openAccess
dc.rights.uri	http://creativecommons.org/licenses/by/3.0/es/	*
dc.source	Articles publicats en revistes (ISGlobal)
dc.subject.classification	SARS-CoV-2
dc.subject.classification	Medicaments antivírics
dc.subject.other	SARS-CoV-2
dc.subject.other	Antiviral agents
dc.title	The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1

Nom:: Chaccour_C_Trials_2020.pdf
Mida:: 444.54 KB
Format:: Adobe Portable Document Format

Descarregar

Col·leccions

Articles publicats en revistes (ISGlobal)